News and Press Releases
Celonic Group and CARBOGEN AMCIS Announce Strategic Alliance to Deliver Fully Integrated ADC Development and Manufacturing Platform
7 October 2025 -- Basel, Switzerland -- CELONIC GROUP, one of the leading “pureplay” Biologics CDMO, and the Carbogen Amcis Group, a leading pharmaceutical process development and Active Pharmaceutical Ingredient (API)...
Category: BioManufacturing, Clinical Trials, Manufacturing and Packing, Other, Pharmaceutical
Posted: October 7, 2025
Lonza’s Synaffix Collaborates with Qurient Therapeutics to Enable Development of Dual-Payload ADC
License agreement centered around technology enabling dual-payload ADC Unique combination of Synaffix’s exatecan-based technology with Qurient’s CDK7 inhibitor. 25 September 2025 -- Amsterdam, The Netherlands and Seongnam-Si, Korea -- Synaffix B.V.,...
Category: Biotechnology, Clinical Trials, Other, Pharmaceutical
Posted: September 25, 2025
Pivot Park, Curie Building Kloosterstraat 9 5349 AB Oss The Netherlands
eXmoor Pharma and Siam Bioscience form strategic partnership to establish leading Cell and Gene Therapy services in Southeast Asia
23 September 2025 -- Bristol, UK and Bangkok, Thailand -- eXmoor Pharma, the integrated cell and gene therapy CDMO with embedded consultancy expertise, and Siam Bioscience, a leading biopharmaceutical company...
Category: BioManufacturing, Manufacturing and Packing, Other, Pharmaceutical
Posted: September 23, 2025
HeartBeat.bio and biotx.ai Sign License and Technology Access Agreement to Identify Novel Targets in Heart Failure
7 July 2025 -- Vienna, Austria and Berlin, Germany -- HeartBeat.bio AG and biotx.ai GmbH today announced a strategic partnership to identify and validate novel therapeutic targets in heart failure. The collaboration combines biotx.ai’s causal...
Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: July 7, 2025
EuroPCR 2025: Late-Breaking Data Demonstrate Sustained Significantly Lower Event Rates With Elixir Medical’s DynamX Bioadaptor Over Drug-Eluting Stent Through Three Years
Sustained durability of treatment effect with significantly lower TLF rates (2.7% versus 7.2%, p=0.030) with DynamX compared to DES Significantly lower rate of Cardiac Death (0.5% versus 3.2%, p=0.033) with...
Category: Biotechnology, Clinical Trials, Other
Posted: May 21, 2025
Cleerly to Present Late-Breaking Clinical Trial Results on Cardiovascular Risk in Women at ACC 25
Cleerly to Present Late-Breaking Findings and Participate in Key ACC 25 Sessions 27 March 2025 -- Illinois, US -- Cleerly, the leader in cardiovascular AI imaging, announces its participation in...
Category: Clinical Trials, Other, Pharmaceutical
Posted: March 27, 2025
ELRIG Announces Prof Rory Johnson and Dr Shalini Andersson as Keynote Speakers at Therapeutic Oligonucleotides 2025
Therapeutic Oligonucleotides 2025: Drugging the Undruggable takes place at AstraZeneca in Gothenburg, Sweden from 14–15 May 25 March 2025 -- Cambridge, UK -- ELRIG, a not-for-profit, volunteer-led organisation for the drug...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 25, 2025
ELRIG (UK) Ltd. Salisbury House, Station Road, Cambridge, CB1 2LA, UK
SGLT2 HYPE – a guideline-relevant, clinical trial aiming to establish SGLT2 inhibitors as a new standard in hypertension therapy, ultimately addressing one of the leading causes of premature mortality in Germany and Europe
25 March 2025 -- Lübeck, Germany -- On January 1, 2025, the European research project SGLT2 HYPE (SGLT2 inhibition for cardiovascular reduction in HYPErtension) was officially launched, receiving €6.99 million...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 25, 2025
Clinigen collaborates with Servier to expand access to specialised oncology and haematology medicines in South Africa
17 March 2025 -- London, UK -- Clinigen, the global speciality pharmaceutical services group, today announced that Equity Pharmaceuticals, part of the Clinigen Group, has entered into a new collaboration...
Category: Drug Delivery, Other, Pharmaceutical
Posted: March 17, 2025
ELRIG Announces Drs Jue Wang and Robert Grundy as Keynote Speakers at Research & Innovation 2025
24 January 2025 -- Cambridge, UK -- The European Laboratory Research & Innovation Group (ELRIG), a not-for-profit, volunteer-led organisation for the drug discovery community, today announced the keynote speakers for Research...
Category: Drug Discovery, Other, Pharmaceutical
Posted: January 24, 2025
ELRIG (UK) Ltd. Salisbury House, Station Road, Cambridge, CB1 2LA, UK
Paris voted the ‘heart of pharma’ in Europe
Pharmapack Europe research reveals Île-de-France is the second-best location in Europe for ‘drug manufacturing’ and to ‘start a biotech’ Paris, France – The global drug delivery and packaging industry arrives...
Category:
Posted: January 13, 2025
Paris Expo, Porte de Versailles - Hall 7.2 | Paris, France
Dewpoint Therapeutics and Mitsubishi Tanabe Pharma Corporation Enter Research Collaboration to Advance Small Molecule Condensate Modulator for ALS
Both companies will collaborate to advance a small molecule condensate modulator targeting TDP-43, with the potential to address the underlying pathology of <97% of ALS patients Mitsubishi Tanabe Pharma Corporation...
Category: BioManufacturing, Drug Discovery
Posted: December 11, 2024
Dewpoint Therapeutics 451 D Street, Suite 104 Boston, MA 02210 USA
Relation announces two strategic collaborations with GSK to advance therapeutics for fibrotic diseases and osteoarthritis
Relation announces two strategic collaborations with GSK to advance therapeutics for fibrotic diseases and osteoarthritis 10 December 2024 -- London, UK -- Relation, an industry leader in deploying computation and...
Category: Drug Discovery, Other, Pharmaceutical
Posted: December 10, 2024
Alnylam Presents Detailed Results from the Positive HELIOS-B Phase 3 Study of Vutrisiran▼ in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress
In the Overall Population, Achieved 28% Reduction in Primary Composite of All-Cause Mortality and Recurrent Cardiovascular Events, and 31% and 36% Reductions in All-Cause Mortality During the 33-36-Month Double-Blind Period...
Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: August 30, 2024
DRUG DISCOVERY 2024: CONNECTING MINDS, TRANSFORMING SCIENCE, EMPOWERING COMMUNITY
We are proud to be media partners of ELRIG's Drug Discovery 2024! Europe’s largest conference for the drug discovery community returns to London, with scientific tracks covering not only therapeutic...
Category: Drug Discovery
Posted: August 29, 2024
ELRIG (UK) Ltd. Salisbury House, Station Road, Cambridge, CB1 2LA, UK
